Antibiotics Utilization for Community Acquired Pneumonia in a Community Hospital Emergency Department

Abstract

Background:

A local health authority in Canada implemented its own Antimicrobial Stewardship Program (ASP) which provide guidelines to clinicians to utilize when treating infectious diseases such as community-acquired pneumonia (CAP). Objectives: The primary objective is to describe antibiotic usage patterns at the community hospital’s emergency department (ED) and to analyze the patterns in relation to ASP goals of reducing risk of infections, adverse drug events and antibiotic resistance, and to identify potential areas of improvement.

Methods:

This retrospective chart review included 156 adult patients with a diagnosis of CAP admitted to a community hospital ED from December 1, 2015 to November 30, 2016.

Results:

50.6% patients were prescribed moxifloxacin across all severity of CAP patients. Low and moderate severity CAP patients were most often prescribed antibiotic duration > 7 days. In low, moderate and high severity CAP patients who were treated using ceftriaxone, 100%, 88.9% and 66.6% patients were treated with ceftriaxone 2000 mg daily respectively.

Conclusions:

Antibiotic prescribing patterns suggest fluoroquinolones were frequently being over-prescribed, ceftriaxone dosages were often too high, and duration of antibiotics for low and moderate severity CAP were too long. More efforts are needed to promote appropriate antibiotic usage and optimize patient care.

Keywords

community-acquired pneumonia antimicrobial stewardship guidelines fluoroquinolone ceftriaxone dosing

Get full access to this article

View all access options for this article.

References

Feagan

Marrie

Lau

Wheeler

Wong

Vandervoort

. Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. Can Med Associat J. 2000;162(10):1415–1420.

NACRS Emergency department visits and length of stay by province/territory, 2015–2016. Published 2016. Accessed May 7, 2017. www.cihi.ca/en/emergency-department-visits-volumes-and-median-length-of-stay

Spellberg

Guidos

Gilbert

, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155–164.

Epidemiology Services. British Columbia Centre for Disease Control. Antimicrobial Resistance Trends in the Province of British Columbia. BC Centre for Disease Control; 2000.

Wortham

Shapiro

Hersh

Lauri

. Burden of ambulatory visits and antibiotic prescribing patterns for adults with community-acquired pneumonia in the United States, 1998 through 2009. J Ame Med Assoc Int Med. 2014;174(9):1520–1522.

Piddock

LJ.

Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance. Brit Med J. 1998;317(7165):1029–1030.

Dingle

Didelot

Quan

, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411–421.

US Food and Drug Administration. FDA Updates Warnings for Fluoroquinolone Antibiotics on Risks of Mental Health and Low Blood Sugar Adverse Reactions. FDA; 2018.

Mandell

Wunderink

Anzueto

, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27–S72.

10.

Santana

Amorim

Soares

, et al. Comparison of CURB-65 and CRB-65 as predictors of death in community-acquired pneumonia in adults admitted to an ICU. Critical Care. 2013;17(S3):P39.

11.

Hand

Antibiotic stewardship. Clinical Medicine. 2013;13(5):499–503.

12.

Accreditation Canada. Required Organizational Practices Handbook. Accreditation Canada; 2017:2016.

13.

Laundy

Gilchrist

Whitney

, eds. Antimicrobial Stewardship. Oxford University Press; 2016.

14.

Antimicrobial Stewardship Annual Report 2016-2017. Fraser Health Antimicrobial Stewardship Program. Published 2017. Accessed June 18 2019. http://medicalstaff.fraserhealth.ca/getattachment/Clinical-Resources/Strips/Clinical-Services/Antimicrobial-Stewardship/Reports/FH-ASP-Annual-Report-2016-17.pdf.aspx/

15.

Urbaniak

Plous

. Research Randomizer (Version 4.0). Published 2013. Accessed June 30, 2017. www.randomizer.org/

16.

Stuck

Minder

Frey

. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963.

17.

ASP Handbook CAP. Fraser health. Published 2017. Accessed June 18, 2019. http://medicalstaff.fraserhealth.ca/getattachment/Clinical-Resources/Strips/Clinical-Services/Antimicrobial-Stewardship/ASP-Handbook-CAP-(2017-08-25).pdf.aspx/

18.

Thiessen

Lloyd

Miller

Juell

Brooke

Katherine

O’Neal

. Assessing guideline-concordant prescribing for community-acquired pneumonia. Int J Clin Pharm. 2017;39(4):674–678.

19.

US Food and Drug Administration. FDA Updates Warnings for Fluoroquinolone Antibiotics. Published July 26, 2016. Accessed June 18, 2019. https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics

20.

Fluoroquinolones—risk of disabling and persistent serious adverse reactions. Published 2017. Accessed September 5, 2017. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/61900a-eng.php

21.

Etminan

Sodhi

Ganjizadeh-Zavareh

, et al. Oral fluoroquinolones and risk of mitral and aortic regurgitation. J Ame Coll Cardiol. 2019;74(11):1444–1450.

22.

Viscogliosi

Chiriac

Braucci

, et al. Predicting delirium in older patients hospitalized for community-acquired pneumonia. J Ame Med Direct Assoc. 2016;17(12):1156–1157.

23.

Stahlmann

Lode

. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193–209.

24.

Segev

Raz

Rubinstein

, et al. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections. Eur J Clin Microbiol Infect Dis. 1995;14(10):851–855.

25.

Telles

Cieslinski

Gasparetto

Felipe Francisco

. Efficacy of ceftriaxone 1 g daily versus 2 g daily for the treatment of community-acquired pneumonia: a systematic review with meta-analysis. Exp Rev Anti Infect Ther. 2019;17(7):501–510.

26.

Uranga

España

Bilbao

, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. J Ame Med Associat Int Med. 2016;176(9):1257–1265.

27.

Chatterjee

Modarai

Naylor

, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis. 2018;18(12):e368–e378.

28.

Deshpande

Pasupuleti

Thota

, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–1961.

29.

Contopoulos-Ioannidis

Ioannidis

JPA

Chew

Lau

. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother. 2001;48(5):691–703.

30.

Amsden

Gray

. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemo. 2001;47(1):61–66.

31.

Cao

Yin

Van Eldere

. Overview of antimicrobial options for mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Resp J. 2017;11(4):419–429.

32.

US Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the Risk of Potentially Fatal Heart Rhythms. US Food and Drug Administration; 2013.

33.

Ray

Murray

Hall

Arbogast

Stein

. Azithromycin and the risk of cardiovascular death. New Eng J Med. 2012;366(20):1881–1890.

34.

Epidemiology Services, British Columbia Centre for Disease Control. Antimicrobial Resistance Trends in the Province of British Columbia. BC Centre for Disease Control; 2014.

35.

Jenkins

Brown

Farrell

. Trends in antibacterial resistance among streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann Clin Microbiol Antimicrob. 2008;7(1):1.

36.

McGeer

Green

Low

; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis. 2006;43(4):432–448.

37.

Granizo

Aguilar

Casal

García-Rey

Dal-Ré

Baquero

. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979–1997). J Antimicrob Chemother. 2000;46(5):767–773.

38.

Public Health Agency of Canada. Canadian antimicrobial resistance surveillance system—update 2018: executive summary. Published 2018. Accessed May 8, 2020. https://www.canada.ca/en/public-health/services/publications/drugs-health-products/canadian-antimicrobial-resistance-surveillance-system-2018-report-executive-summary.html

39.

Klugman

. Clinical impact of antibiotic resistance in respiratory tract infections. Int J Antimicrob Agents. 2007;29(suppl 1):S6–S10.

40.

Endimiani

Brigante

Bettaccini

Francesco

Paolo

Antonio

. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BioMed Cen Infect Dis. 2005;5(1):106.

41.

Llinares

Menéndez

Mujal

, et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Revista Española de Quimioterapia. 2014;27(1):69–86.

42.

Schouten

Hulscher

Kullberg

Bart Jan

Van Meer

WMD

Richard Grol

PTM

. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. British Med J Qual Safe. 2007;16(2):143–149.